vs

Side-by-side financial comparison of Figma, Inc. (FIG) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

MADRIGAL PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($321.1M vs $274.2M, roughly 1.2× Figma, Inc.). MADRIGAL PHARMACEUTICALS, INC. runs the higher net margin — -18.2% vs -400.1%, a 381.9% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 38.0%). Figma, Inc. produced more free cash flow last quarter ($49.5M vs $-133.8M).

Figma is a collaborative web application for interface design, with additional offline features enabled by desktop applications for macOS and Windows. The feature set of Figma focuses on user interface and user experience design, with an emphasis on real-time collaboration, utilizing a variety of vector graphics editor and prototyping tools. The Figma mobile app for Android and iOS allows viewing and interacting with Figma prototypes in real-time on mobile and tablet devices.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

FIG vs MDGL — Head-to-Head

Bigger by revenue
MDGL
MDGL
1.2× larger
MDGL
$321.1M
$274.2M
FIG
Growing faster (revenue YoY)
MDGL
MDGL
+172.7% gap
MDGL
210.8%
38.0%
FIG
Higher net margin
MDGL
MDGL
381.9% more per $
MDGL
-18.2%
-400.1%
FIG
More free cash flow
FIG
FIG
$183.3M more FCF
FIG
$49.5M
$-133.8M
MDGL

Income Statement — Q3 FY2025 vs Q4 FY2025

Metric
FIG
FIG
MDGL
MDGL
Revenue
$274.2M
$321.1M
Net Profit
$-1.1B
$-58.6M
Gross Margin
69.4%
Operating Margin
-414.6%
-18.6%
Net Margin
-400.1%
-18.2%
Revenue YoY
38.0%
210.8%
Net Profit YoY
-6933.0%
1.4%
EPS (diluted)
$-2.72
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FIG
FIG
MDGL
MDGL
Q4 25
$321.1M
Q3 25
$274.2M
$287.3M
Q2 25
$249.6M
$212.8M
Q1 25
$137.3M
Q4 24
$103.3M
Q3 24
$198.6M
$62.2M
Q2 24
$177.2M
Q1 24
$0
Net Profit
FIG
FIG
MDGL
MDGL
Q4 25
$-58.6M
Q3 25
$-1.1B
$-114.2M
Q2 25
$28.2M
$-42.3M
Q1 25
$-73.2M
Q4 24
$-59.4M
Q3 24
$-15.6M
$-107.0M
Q2 24
$-827.9M
Q1 24
$-147.5M
Gross Margin
FIG
FIG
MDGL
MDGL
Q4 25
Q3 25
69.4%
Q2 25
88.8%
Q1 25
96.7%
Q4 24
Q3 24
90.6%
Q2 24
77.7%
Q1 24
Operating Margin
FIG
FIG
MDGL
MDGL
Q4 25
-18.6%
Q3 25
-414.6%
-39.7%
Q2 25
0.8%
-22.2%
Q1 25
-57.8%
Q4 24
-64.8%
Q3 24
-23.8%
-187.1%
Q2 24
-504.7%
Q1 24
Net Margin
FIG
FIG
MDGL
MDGL
Q4 25
-18.2%
Q3 25
-400.1%
-39.8%
Q2 25
11.3%
-19.9%
Q1 25
-53.4%
Q4 24
-57.5%
Q3 24
-7.9%
-172.0%
Q2 24
-467.2%
Q1 24
EPS (diluted)
FIG
FIG
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$-2.72
$-5.08
Q2 25
$0.00
$-1.90
Q1 25
$-3.32
Q4 24
$-2.50
Q3 24
$-0.07
$-4.92
Q2 24
$-4.39
Q1 24
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FIG
FIG
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$1.6B
$198.7M
Total DebtLower is stronger
$339.9M
Stockholders' EquityBook value
$1.4B
$602.7M
Total Assets
$2.1B
$1.3B
Debt / EquityLower = less leverage
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FIG
FIG
MDGL
MDGL
Q4 25
$198.7M
Q3 25
$1.6B
$295.7M
Q2 25
$1.6B
$186.2M
Q1 25
$183.6M
Q4 24
$100.0M
Q3 24
$416.1M
$232.7M
Q2 24
$586.1M
Q1 24
$622.5M
Total Debt
FIG
FIG
MDGL
MDGL
Q4 25
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$117.1M
Q2 24
Q1 24
$116.1M
Stockholders' Equity
FIG
FIG
MDGL
MDGL
Q4 25
$602.7M
Q3 25
$1.4B
$625.7M
Q2 25
$1.4B
$696.0M
Q1 25
$710.6M
Q4 24
$754.4M
Q3 24
$1.2B
$777.2M
Q2 24
$862.4M
Q1 24
$850.8M
Total Assets
FIG
FIG
MDGL
MDGL
Q4 25
$1.3B
Q3 25
$2.1B
$1.4B
Q2 25
$2.0B
$1.0B
Q1 25
$996.6M
Q4 24
$1.0B
Q3 24
$1.1B
Q2 24
Q1 24
$1.1B
Debt / Equity
FIG
FIG
MDGL
MDGL
Q4 25
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.15×
Q2 24
Q1 24
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FIG
FIG
MDGL
MDGL
Operating Cash FlowLast quarter
$51.2M
$-133.5M
Free Cash FlowOCF − Capex
$49.5M
$-133.8M
FCF MarginFCF / Revenue
18.0%
-41.7%
Capex IntensityCapex / Revenue
0.6%
0.1%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FIG
FIG
MDGL
MDGL
Q4 25
$-133.5M
Q3 25
$51.2M
$79.8M
Q2 25
$-47.1M
Q1 25
$-88.9M
Q4 24
$-104.5M
Q3 24
$-67.0M
Q2 24
Q1 24
$-149.2M
Free Cash Flow
FIG
FIG
MDGL
MDGL
Q4 25
$-133.8M
Q3 25
$49.5M
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q2 24
Q1 24
$-149.5M
FCF Margin
FIG
FIG
MDGL
MDGL
Q4 25
-41.7%
Q3 25
18.0%
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q2 24
Q1 24
Capex Intensity
FIG
FIG
MDGL
MDGL
Q4 25
0.1%
Q3 25
0.6%
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

FIG
FIG

Non Us$147.4M54%
US$126.8M46%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons